Chronic Pain Clinical Trial
Official title:
Optimization of Non-Invasive Brain Stimulation for Diabetic Neuropathy
The purpose of this study is to assess the effects of Transcranial Direct Current Stimulation (tDCS) in combination with Transcranial ultrasound (TUS) for the treatment of pain and functional limitations in subjects with Diabetic Neuropathic Pain.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | May 7, 2025 |
Est. primary completion date | June 7, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Able to provide informed consent to participate in the study. 2. Subjects between 40 to 80 years old. 3. Having diabetic neuropathic pain, involving at least 1 foot, with existing pain for at least 6 months, and having pain on at least half the days in the past 6 months with an average of at least a 4 on a 0-10 VAS scale). 4. Having pain resistant to common analgesics and medications for first-line therapy of chronic pain such as Tylenol, Aspirin, Ibuprofen, Soma, Parafon Forte DCS, Zanaflex, Codeine, etc. 5. Must have the ability to feel pain as self-reported. Exclusion Criteria: 1. Subject is pregnant. 2. Contraindications to tDCS in conjunction with TUS, i.e. metallic implant in the brain or implanted brain medical devices 3. History of alcohol or drug abuse within the past 6 months as self-reported. 4. Use of carbamazepine within the past 6 months as self-reported. 5. Suffering from severe depression (with a PHQ 9 score of = 10). 6. History of neurological disorders as self-reported. 7. History of unexplained fainting spells as self-reported. 8. History of severe head injury resulting in more than a momentary loss of consciousness as self-reported. 9. History of neurosurgery as self-reported. 10. Unstable pain (defined as pain intensities that vary by more than 4 points on 0-10 VAS scale over the 1-week period of trial run-in). |
Country | Name | City | State |
---|---|---|---|
United States | Ciro Ramos Estebanez | Chicago | Illinois |
United States | University Hospitals Cleveland Medical Center/ Dahms Clinical Research Unit | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
Case Western Reserve University | Highland Instruments, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in pain as measured by the Visual Analog Scale (VAS) | The scale will assess a patient's pain intensity on a scale from 0 (no pain) to 10 (worst pain imaginable). Changes in VAS for Pain will be measured to determine whether anodal transcranial direct current stimulation (tDCS) in conjunction with transcranial ultrasound (TUS) (applied in a diagnostic mode) is effective in reducing pain of subjects with diabetic neuropathic pain. | Measured for approximately 3 months | |
Secondary | Changes in the Verbal Rating Scale (VRS) for Pain | The VRS for Pain is a categorical scale of pain with categories: none, mild, moderate, severe pain intensity. Changes in VRS for Pain will be measured in order to determine whether anodal transcranial direct current stimulation (tDCS) in conjunction. with transcranial ultrasound (TUS) (applied in a diagnostic mode) is effective in reducing pain of subjects with diabetic neuropathic pain. | Measured for approximately 3 months | |
Secondary | Changes in Conditional Pain Modulation | Changes in Conditional Pain Modulation (CPM) will be measured in order to determine whether anodal transcranial direct current stimulation (tDCS) in conjunction with transcranial ultrasound (TUS) (applied in a diagnostic mode) is effective in increasing the pain pressure threshold in subjects with diabetic neuropathic pain. | Measured for approximately 3 months | |
Secondary | Changes in Visual Analog Scalefor Mood (VAMS) | The VAS for Mood will investigate Anxiety, Depression, Stress, and Sleepiness. The Subscales are as follows: The anxiety scale will assess a patient's anxiety on a scale from 0 (not anxious) to 10 (very anxious). The depression scale will assess a patient's depression on a scale from 0 (not depressed) to 10 (very depressed). The stress scale will assess a patient's stress on a scale from 0 (not stressed) to 10 (very stressed). The sleepiness scale will assess a patient's depression on a scale from 0 (not sleepy) to 10 (very sleepy). |
Measured for approximately 3 months | |
Secondary | Montreal Cognitive Assessment | The investigators will monitor the safety of tDCS and TUS in subjects by measuring any changes in cognition. Scores range from lowest being 0 to highest being 30. | Measured for approximately 3 months | |
Secondary | 4-choice reaction time | This is an attentional task that measures the time for a subject response to stimuli (in seconds) with shorter times being better. | Measured for approximately 3 months | |
Secondary | N-back tests | Assesses registration and immediate recall on a scale of the number of items correctly responded to | Measured for approximately 3 months | |
Secondary | Electroencephalography | Investigators will measure electroencephalogram (EEG) electrical activity (EEG amplitude and EEG frequency) as function of time. | Measured for approximately 3 months | |
Secondary | Walking test | The investigators will measure if there are changes in the walking speed, gait asymmetry, stride length, and walking smoothness of the subject from the beginning of the study to the end | Measured for approximately 3 months | |
Secondary | Functional reach test | The investigators will measure changes in subjects ability to complete the functional reach test across the duration of study. | Measured for approximately 3 months | |
Secondary | Study 36-Item Short Form (SF-36) | This is a health survey using a scale from 0 (worst) to 100 (best) | Measured for approximately 3 months | |
Secondary | Patient Health Questionnaire (PHQ-9) | This questionnaire screens for depression with a score of 0 (best) to 27 (worst) | Measured for approximately 3 months | |
Secondary | American Pain Foundation Pain and Medication Diary | The pain sub-scale measures pain intensity from 0 (best) to 10 (worst) | Measured for approximately 3 months | |
Secondary | Multidimensional Pain Inventory (MPI) | This pain scale measures aspects of pain from 0 (best) to 6 (worst) | Measured for approximately 3 months | |
Secondary | Brief Pain Inventory-DPN | This pain scale measures aspects of pain from 0 (no pain) to 10 (worst) | Measured for approximately 3 months | |
Secondary | Adverse events | At each session after stimulation begins, subjects will complete a questionnaire to evaluate potential adverse effects of stimulation (headache, neck pain, mood alterations, and seizures) on a 5-point scale (0 being best and 5 worst). The scale will also be administered at the follow-up. | Measured for approximately 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|